medigraphic.com
ISSN 2954-3835 (Digital)
ISSN 2683-2828 (Impreso)

2024, Número S1

<< Anterior Siguiente >>

Cardiovasc Metab Sci 2024; 35 (S1)


Anticoncepción hormonal en mujeres con hipertensión

Sánchez-Aguirre F, Fierro-Fuentes J, Basurto-Acevedo L

Idioma: Inglés [English version]
Referencias bibliográficas: 15
Paginas: s28-31
Archivo PDF: 167.69 Kb.





REFERENCIAS (EN ESTE ARTÍCULO)

  1. Chandra A, Martinez GM, Mosher WD, Abma JC, Jones J. Fertility, family planning, and reproductive health of U.S. women: data from the 2002 National Survey of Family Growth. Vital Health Stat 23. 2005; (25): 1-160.

  2. Margolis KL, Adami HO, Luo J, Ye W, Weiderpass E. A prospective study of oral contraceptive use and risk of myocardial infarction among Swedish women. Fertil Steril. 2007; 88 (2): 310-316. doi: 10.1016/j.fertnstert.2006.11.206.

  3. Kaunitz AM. Clinical practice. Hormonal contraception in women of older reproductive age. N Engl J Med. 2008; 358 (12): 1262-1270. doi: 10.1056/NEJMcp0708481. PMID: 18354104.

  4. Chasan-Taber L, Willett WC, Manson JE, Spiegelman D, Hunter, DJ, Curhan G et al. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation. 1996; 94 (3): 483-489. doi: 10.1161/01.CIR.94.3.483.

  5. Cardoso F, Polonia J, Santos A, Silva-Carvalho J, Ferreira-de-Almeida J. Low-dose oral contraceptives and 24-hour ambulatory blood pressure. Int J Gynaecol Obstet. 1997; 59 (3): 237-243. doi: 10.1016/S0020-7292(97)00239.

  6. Shufelt CL, Bairey Merz CN. Contraceptive hormone use and cardiovascular disease. J Am Coll Cardiol. 2009; 53 (3): 221-231. doi: 10.1016/j.jacc.2008.09.042.

  7. Glisic M, Shahzad S, Tsoli S, Chadni, M, Asllanaj E, Rojas LZ et al. Association between progestin-only contraceptive use and cardiometabolic outcomes: A systematic review and meta-analysis. Eur J Prev Cardiol. 2018; 25 (10): 1042-1052. doi: 10.1177/2047487318774847.

  8. Virani Salim S, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP et al. Heart disease and stroke statistics—2020 update: a report from the American Heart Association. Circulation. 2020; 141 (9): e139-e596. doi: 10.1161/CIR.0000000000000757.

  9. Shamah-Levy T, Romero-Martínez M, Barrientos-Gutiérrez T, Cuevas-Nasu L, Bautista-Arredondo S, Colchero MA et al. Encuesta Nacional de Salud y Nutrición 2020 sobre Covid-19. Resultados nacionales. Cuernavaca, México: Instituto Nacional de Salud Pública; 2021. Disponible en: https://ensanut.insp.mx/encuestas/ensanutcontinua2020/doctos/informes/ensanutCovid19ResultadosNacionales.pdf

  10. ACOG Practice Bulletin No. 206: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2019; 133 (2): e128-e150. doi: 10.1097/AOG.0000000000003072.

  11. DeStefano F, Merritt RK, Anda RF, Casper ML, Eaker ED et al. Trends in nonfatal coronary heart disease in the United States, 1980 through 1989. Arch Intern Med. 1993; 153 (21): 2489-2494. doi: 10.1001/archinte.1993.00410210117013.

  12. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA. 1991; 265 (14): 1861-1867. doi: 10.1001/jama.1991.03460140089033.

  13. Shufelt C, LeVee A. Hormonal contraception in women with hypertension. JAMA. 2020; 324 (14): 1451-1452. doi: 10.1001/jama.2020.11935.

  14. Fardoun M, Dehaini H, Shaito A, Mesmar J, El-Yazbi A, Badran A et al. The hypertensive potential of estrogen: An untold story. Vascul Pharmacol. 2020; 124: 106600. doi: 10.1016/j.vph.2019.106600.

  15. Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB et al. U.S. Medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep. 2016; 65 (3): 1-103. doi: 10.15585/mmwr.rr6503a1.




2020     |     www.medigraphic.com